Annual Report 2024

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2024 84 The United Laboratories International Holdings Limited Annual Report 2024 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information (Continued) (a) Segment revenue and results (Continued) Year ended 31 December 2023 Intermediate Bulk Finished Segments products medicine products total Elimination Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 REVENUE External sales 2,316,878 6,399,180 5,023,821 13,739,879 – 13,739,879 Inter-segment sales 3,436,223 993,005 – 4,429,228 (4,429,228) – Segment revenue 5,753,101 7,392,185 5,023,821 18,169,107 (4,429,228) 13,739,879 Segment profit before research and development expenses 2,098,205 969,400 1,044,429 4,112,034 Research and development expenses (included in the measurement of segment profit) (113,744) (187,563) (455,941) (757,248) RESULT Segment profit 1,984,461 781,837 588,488 3,354,786 Share of results of an associate 143 Unallocated other income 152,447 Unallocated corporate expenses (166,674) Unallocated other gains and losses, net 69,790 Impairment losses reversed under expected credit loss model, net 552 Finance costs (66,896) Profit before taxation 3,344,148